- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
- Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Pacira Appoints Frank D. Lee as Chief Executive Officer
More ▼
Key statistics
On Tuesday, Pacira Biosciences Inc (PCRX:NSQ) closed at 26.81, 4.18% above its 52-week low of 25.74, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 26.24 |
---|---|
High | 27.09 |
Low | 26.19 |
Bid | 10.79 |
Offer | 42.00 |
Previous close | 26.81 |
Average volume | 492.49k |
---|---|
Shares outstanding | 46.50m |
Free float | 45.94m |
P/E (TTM) | 39.49 |
Market cap | 1.25bn USD |
EPS (TTM) | 0.6789 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:00 BST.
More ▼